| Variable | Total population (n=25 519) | 5-Year interval |
Relative change (difference, %) | p for trend1 | ||
|---|---|---|---|---|---|---|
| 1994-1999 (n=8539) | 2000-2005 (n=9729) | 2006-2010 (n=7251) | ||||
| Total population | ||||||
| Aspirin use at baseline2 | 22 149 (87.0) | 6806 (80.0) | 8391 (87.0) | 6952 (96.0) | 16 | < 0.001 |
| Beta-blocker use at baseline | 18 284 (72.0) | 5373 (63.0) | 7214 (75.0) | 5697 (79.0) | 16 | < 0.001 |
| ACE inhibitor use at baseline | 9119 (36.0) | 1733 (20.0) | 3799 (40.0) | 3587 (50.0) | 30 | < 0.001 |
| Lipid lowering drug use at baseline | 12 767 (51.0) | 2505 (30.0) | 5128 (54.0) | 5134 (71.0) | 29 | < 0.001 |
| Aspirin use at discharge | 24 076 (96.0) | 7892 (94.0) | 9171 (95.0) | 7013 (98.0) | 4 | < 0.001 |
| Beta-blocker use at discharge | 19 938 (79.0) | 5761 (68.0) | 7901 (82.0) | 6276 (88.0) | 20 | < 0.001 |
| ACE inhibitor use at discharge | 12 256 (49.0) | 2392 (28.0) | 5437 (57.0) | 4427 (62.0) | 34 | < 0.001 |
| Lipid lowering drug use at discharge | 18 676 (74.0) | 4080 (48.0) | 7978 (83.0) | 6618 (92.0) | 44 | < 0.001 |
| Men | ||||||
| Aspirin use at baseline | 15 738 (88.0) | 4825 (80.0) | 5936 (88.0) | 4977 (97.0) | 17 | < 0.001 |
| Beta-blocker use at baseline | 12 841 (72.0) | 3746 (62.0) | 5054 (75.0) | 4041 (79.0) | 17 | < 0.001 |
| ACE inhibitor use at baseline | 6362 (35.0) | 1183 (20.0) | 2634 (39.0) | 2545 (49.0) | 29 | < 0.001 |
| Lipid lowering drug use at baseline | 9184 (52.0) | 1792 (30.0) | 3679 (55.0) | 3713 (72.0) | 42 | < 0.001 |
| Aspirin use at discharge | 17 161 (96.0) | 5640 (94.0) | 6511 (96.0) | 5010 (98.0) | 4 | < 0.001 |
| Beta-blocker use at discharge | 14 100 (79.0) | 4054 (68.0) | 5577 (82.0) | 4469 (87.0) | 19 | < 0.001 |
| ACE inhibitor use at discharge | 8595 (48.0) | 1630 (27.0) | 3790 (56.0) | 3175 (62.0) | 33 | < 0.001 |
| Lipid lowering drug use at discharge | 13 370 (75.0) | 2920 (49.0) | 5712 (84.0) | 4738 (93.0) | 54 | < 0.001 |
| Women | ||||||
| Aspirin use at baseline | 6411 (87.0) | 1981 (80.0) | 2455 (87.0) | 1975 (95.0) | 15 | < 0.001 |
| Beta-blocker use at baseline | 5443 (74.0) | 1627 (65.0) | 2160 (77.0) | 1656 (80.0) | 15 | < 0.001 |
| ACE inhibitor use at baseline | 2757 (37.0) | 550 (22.0) | 1165 (41.0) | 1042 (50.0) | 28 | < 0.001 |
| Lipid lowering drug use at baseline | 3538 (49.0) | 713 (29.0) | 1449 (52.0) | 1421 (68.0) | 39 | < 0.001 |
| Aspirin use at discharge | 6915 (94.0) | 2252 (92.0) | 2660 (94.0) | 2003 (97.0) | 5 | < 0.001 |
| Beta-blocker use at discharge | 5838 (80.0) | 1707 (70.0) | 2324 (82.0) | 1807 (88.0) | 18 | < 0.001 |
| ACE inhibitor use at discharge | 3661 (50.0) | 762 (31.0) | 1647 (58.0) | 1252 (61.0) | 30 | < 0.001 |
| Lipid lowering drug use at discharge | 5306 (72.0) | 1160 (47.0) | 2266 (81.0) | 1880 (91.0) | 44 | < 0.001 |
Values are presented as number of patients (%).
ACE, angiotensin converting enzyme.
1
The Cochran-Armitage trend test was used to compare the proportions.
2
Mean value at baseline for answering “yes” to whether the medication was used within 3 days before the percutaneous coronary intervention.